Is the swine flu going to be pandemic?

Capsid
It just seemed odd that you were constricting the definitions in such a way as you did in the paragraph I quoted.
Only Type A and only influenza

Maybe you were using shorthand? :boggled:

I think that's where a lot of confusion is arising - and the WHO apparently will address the problem.......what the various situations that are announced actually imply.

The level of pandemic index etc does not equate with the level of threat of the particular disease/strain to the individual etc
All I said was that type A influenza causes pandemics. Type Bs cause epidemics. Your quote confirmed that. Are you assuming I meant that only influenza can cause pandemics? I was just talking about pandemic flu as this is what the thread is about.
 
Last edited:
I'm still slightly baffled by the situation in Scotland. It got here all right, but it seems curiously reluctant to spread person-to-person.

One honeymoon couple, went back to work after returning from Mexico. Husband infected a five-a-side football mate. No other known spread.

One traveller from Texas, doesn't seem to have passed it on at all.

One man employed in Mexico arrived home on leave with symptoms and passed it to his son before flying out again.

Five cases in all. Maybe about to become six as there's a probable being tested. However "the vast majority of people tested are proving negative for the virus". They seem to be testing all the contacts they can find.

Why isn't it all over the place? These people must have had many contacts, not to mention all the rest of the passengers on the planes involved, including the people the working father flew in with and met while he was home.

I don't get it.

Rolfe.
 
Capsid - yes - you seemed to imply something you did not intend...just wanted it clarified. It's been beat to death.

••

Rolfe I suspect there is something about survival time on surfaces of airborne for various strains that impacts on how contagious it is and how many particles you need to be in contact with to have an infection ( of course it's statistical ).

The Nat'L Geo series running this weekend covered off various situations like that - the one on ebola was nasty.....just a few floating particles and .......:eusa_boohoo:

The was crazy an ebola outbreak 30 miles from Washington DC and dumb luck it was a different strain that did not affect humans....

http://www.who.int/mediacentre/factsheets/fs103/en/

http://www.cdc.gov/mmwr/preview/mmwrhtml/00001512.htm
 
Is this a discussion of sharing information, or are you still trying to argue some point?
I'm mostly just trying to figure it out. I've often found that trying to argue a point can help to facilitate better understanding, but since you and I seem to have a way of getting under each other's skin, I'm thinking there might be more to be gained by keeping the emphasis more on the information sharing aspect.

From everything I'm seeing, it looks like the WHO and the CDC and the vaccine manufacturers are still at the stage of trying to figure it out themselves. I consider it hasty at this point to regard it as a foregone conclusion that a vaccine against this virus will be available if it returns in the fall, but if you have some inside information you'd like to share, I'd appreciate seeing it. If you're mostly going by an intuitive feel for the situation, then I can accept that. We don't always agree on things, but your perspective, on this issue in particular, is not one I can casually brush aside. That gets lost when our discussions become heated, and I'd like to try to avoid that, beginning with apologizing for my previous excesses.

At this point, I can almost guarantee you, the vaccine will be made.
I'm quite eager to accept that, but, respectfully, it would make me feel a lot better if those involved in the actual decision making process were as unequivocal about it as you are. The problem seems to center on the fact that a single manufacturing facility cannot produce more than one vaccine component at a time (and it's not hard to understand why, either). They're talking about stopping production of at least some components of the seasonal vax in order to permit production of the S-OIV vax to begin, which suggests that overall, production of the seasonal vax is still some ways away from being complete.

From the standpoint of a manufacturer (a for-profit enterprise), flu vax is enough of a gamble already. Mismatch is always a possibility. Uptake is unpredictable. The entire year's production becomes as worthless at the end of the season as a trainload of fresh cut Christmas trees on December 26th. Mainstream media play a critical role in shaping the way the public perceives and responds to the threat posed by either seasonal or pandemic influenza, and there is effectively zero accountability (to them, it's just so much grist for the entertainment industry mill). Most pharmaceutical companies have concluded that it's just not worth the hassle. If it's a choice between making seasonal vaccine and making a vaccine (perhaps a univalent vaccine) for a strain that may or may not even be widely circulating by the time the lots are finished, that makes it an even tougher call.

Not only that, but the collateral damage from the 1976 Swine flu incident looms large in the minds of all. The virologists and epidemiologists and vaccine manufacturers and public health officials are very much aware that the science of influenza has advanced considerably since that time, as has the surveillance infrastructure and methodology, quality control in vaccine manufacturing, etc (as well as that the whole Guillain-Barre thing was way overblown). The general public, however, is not. Regardless of what the decision is or what the outcome is, this will impact public confidence in the system for many years to come. Scientific illiteracy can be viewed as a public health problem. (I expect you to enthusiastically agree here).

I am, however, very familiar with the US vaccine use and recommendations because for the last 19 years I have given thousands of doses of vaccines every year including between 1000-2000 flu shots and I take the time to know everything I can about vaccines I prescribe for that many people.
Not to diminish that (in all sincerity), but this raises an important point: The current situation is unique in several aspects. It's been forty years since the last notable influenza pandemic, and no clinician alive today has hands-on experience in dealing with a highly virulent pandemic influenza. We're not even sure about the extent to which what we're seeing now might be regarded as primarily an artifact of improved surveillance capabilities. There has been a lot of discussion about possible response measures to a pandemic, and how well present infrastructure is set up to handle that, and we are getting a better look at that.

"Better than ever, but still not very good, and we're basically making a lot of it up as we go along" -- is one way I might phrase it.
 
Well you'll get some answers here as of today

First analysis of swine flu spread supports pandemic plan

* 19:00 11 May 2009 by Andy Coghlan
* For similar stories, visit the Epidemics and Pandemics Topic Guide

H1N1 swine flu is spreading fast enough to justify the preparations for a pandemic, say epidemiologists who've analysed the pattern of spread so far.

"The message is that the epidemic is spreading very much as expected based on past flu epidemics," says Christophe Fraser of Imperial College London, and co-leader of the analysis team.

The results suggest that the H1N1 virus is showing "sustained human-to-human transmission", thereby justifying the WHO's pandemic phase 5 rating, one short of the most severe.

more

http://www.newscientist.com/article...-swine-flu-spread-supports-pandemic-plan.html
 
I'm still slightly baffled by the situation in Scotland. It got here all right, but it seems curiously reluctant to spread person-to-person.

One honeymoon couple, went back to work after returning from Mexico. Husband infected a five-a-side football mate. No other known spread.

One traveller from Texas, doesn't seem to have passed it on at all.

One man employed in Mexico arrived home on leave with symptoms and passed it to his son before flying out again.

Five cases in all. Maybe about to become six as there's a probable being tested. However "the vast majority of people tested are proving negative for the virus". They seem to be testing all the contacts they can find.

Why isn't it all over the place? These people must have had many contacts, not to mention all the rest of the passengers on the planes involved, including the people the working father flew in with and met while he was home.

I don't get it.

Rolfe.
Think of it like a fire. Sometimes a spark fails to light it. But get a few more sparks and since the fuel conditions are conducive, eventually one of the sparks will get the fire started.
 
I'm mostly just trying to figure it out. I've often found that trying to argue a point can help to facilitate better understanding, but since you and I seem to have a way of getting under each other's skin, I'm thinking there might be more to be gained by keeping the emphasis more on the information sharing aspect.
You're not under my skin so much as you have been trying to argue with expertise you don't have. Instead of recognizing and keeping an open mind to the fact you don't have that expertise, you've tried to argue when you don't know what you are talking about instead of taking the opportunity to learn.


From everything I'm seeing, it looks like the WHO and the CDC and the vaccine manufacturers are still at the stage of trying to figure it out themselves. I consider it hasty at this point to regard it as a foregone conclusion that a vaccine against this virus will be available if it returns in the fall, but if you have some inside information you'd like to share, I'd appreciate seeing it. If you're mostly going by an intuitive feel for the situation, then I can accept that. We don't always agree on things, but your perspective, on this issue in particular, is not one I can casually brush aside. That gets lost when our discussions become heated, and I'd like to try to avoid that, beginning with apologizing for my previous excesses.
Apology accepted.

The inside information I have is not a "hunch". It is familiarity with the process. If there was a decision to be made to choose one vaccine over another, then the decision would be more iffy. Apparently Europe may be having more of a problem with this. Our manufacturing facilities are separate as each has to be approved by the FDA of the respective countries the vaccines are licensed for.

If this new virus were way less lethal than seasonal flu, the decision would be iffy. But we have a virus that is at least as lethal as an average flu virus, it is novel and spreading consistently and fast. And the manufacturing capacity is available or soon will be. For example, Sanofi just got a new facility licensed in the US. That facility would not be in the process of making seasonal flu vaccine because this is too late to start and it was just licensed. It's open to make new flu vaccine.

May 6, 2009; FDA Approves New Influenza Vaccine Production Facility

And there was recent approval for some facility in Australia to make an H5N1 vaccine. There could be some vaccine manufacturing capacity there, I don't know.

Mar 26, 2009; EMERFLU®, pandemic influenza vaccine for humans, approved in Australia

Sanofi is only one of several companies that make flu vaccine. They have all been ramping up production for several years.


Because of the 1976 experience with GBS and the swine flu vaccine; because the vaccine factor involved in the GBS was never identified; because the CDC was once burned, twice shy; because the current new virus so far has been more lethal in young adults than usual; and because there so far is a pattern of fatalities in people with pre-existing conditions, you can conclude from that, CDC will recommend the manufacturers go ahead, and that the recommendations for getting the vaccine will be limited unless the disease pattern changes as this flu strain evolves in the southern hemisphere.

I'm quite eager to accept that, but, respectfully, it would make me feel a lot better if those involved in the actual decision making process were as unequivocal about it as you are.
You are confusing official public announcements with actual decisions being made. You seem to think that those of us working in this field are no more informed than the news media. I assure you, I am more informed than the news media and official public health announcements come after decisions are made, not as they are made.

If a person knows what goes into the decision, and is familiar with the actual research on this epidemic being published and shared via networking and conferences, a person does know with some confidence what the decisions are going to be.


The problem seems to center on the fact that a single manufacturing facility cannot produce more than one vaccine component at a time (and it's not hard to understand why, either). They're talking about stopping production of at least some components of the seasonal vax in order to permit production of the S-OIV vax to begin, which suggests that overall, production of the seasonal vax is still some ways away from being complete.
No, you have this all wrong. 3 strains go into every annual flu vaccine. The 3 strains are always produced simultaneously by the manufacturers. No one makes 1 or 2 strain flu vaccine. Flu vaccine has been trivalent for decades.

The strains are decided by the WHO every 6 months and seed virus stocks are provided to the manufacturers every 6 months. (In addition, seed virus strains are provided by the WHO to these companies for research on a regular basis upon request but that is another subject.) Production starts every spring depending on the hemisphere and is ready by fall. There have been delays when seed strains chosen don't grow quickly enough. Unless that happens, I get my flu vaccine in August or September every year. My understanding is the US companies have not experienced any unusual delays so far this year.

From the standpoint of a manufacturer (a for-profit enterprise), flu vax is enough of a gamble already. Mismatch is always a possibility. Uptake is unpredictable. The entire year's production becomes as worthless at the end of the season as a trainload of fresh cut Christmas trees on December 26th. Mainstream media play a critical role in shaping the way the public perceives and responds to the threat posed by either seasonal or pandemic influenza, and there is effectively zero accountability (to them, it's just so much grist for the entertainment industry mill). Most pharmaceutical companies have concluded that it's just not worth the hassle. If it's a choice between making seasonal vaccine and making a vaccine (perhaps a univalent vaccine) for a strain that may or may not even be widely circulating by the time the lots are finished, that makes it an even tougher call.
Again, you just don't know the current market. Since the recent flu vaccine shortages, the CDC intervened and has guaranteed a minimum market for the vaccines to prevent shortages from market forces. New companies moved into the flu vaccine market and all of them have ramped up production capacity. There is no reason they want that capacity sitting idle.

See, this is what I am talking about. You just don't know what the facts are. You are a decade out of date.

Not only that, but the collateral damage from the 1976 Swine flu incident looms large in the minds of all. The virologists and epidemiologists and vaccine manufacturers and public health officials are very much aware that the science of influenza has advanced considerably since that time, as has the surveillance infrastructure and methodology, quality control in vaccine manufacturing, etc (as well as that the whole Guillain-Barre thing was way overblown). The general public, however, is not. Regardless of what the decision is or what the outcome is, this will impact public confidence in the system for many years to come. Scientific illiteracy can be viewed as a public health problem. (I expect you to enthusiastically agree here).
Which is why I can say with certainty that unless the new strain changes course for the worse, you will see the new vaccine only recommended for people in specific risk categories.

Not to diminish that (in all sincerity), but this raises an important point: The current situation is unique in several aspects. It's been forty years since the last notable influenza pandemic, and no clinician alive today has hands-on experience in dealing with a highly virulent pandemic influenza.
Oh pllueease! I've been in health care since 1976 and I am hardly the oldest clinician around. The pandemic flu plans have been under development for years. You don't have to have been around in 1918 to get the picture.

We're not even sure about the extent to which what we're seeing now might be regarded as primarily an artifact of improved surveillance capabilities. There has been a lot of discussion about possible response measures to a pandemic, and how well present infrastructure is set up to handle that, and we are getting a better look at that.

"Better than ever, but still not very good, and we're basically making a lot of it up as we go along" -- is one way I might phrase it.
You sorely underestimate the quality of the health care system in the US and I assume in the other developed nations.
 
Here's one of the sources they are discussing:

Pandemic Potential of a Strain of Influenza A (H1N1) : Early Findings
A novel influenza A (H1N1) virus has spread rapidly across the globe. Judging its pandemic potential is difficult with limited data, but nevertheless essential to inform appropriate health responses. By analyzing the outbreak in Mexico, early data on international spread, and viral genetic diversity, we make an early assessment of transmissibility and severity. Our estimates suggest that 23,000 (range 6,000-32,000) individuals had been infected in Mexico by late April, giving an estimated case fatality ratio (CFR) of 0.4% (range 0.3% to 1.5%) based on confirmed and suspect deaths reported to that time. In a community outbreak in the small community of La Gloria, Veracruz no deaths were attributed to infection, giving an upper 95% bound on CFR of 0.6%. Thus while substantial uncertainty remains, clinical severity appears less than that seen in 1918 but comparable with that seen in 1957. Clinical attack rates in children in La Gloria were twice that in adults (<15 years-of-age: 61%, ≥15: 29%). Three different epidemiological analyses gave R0 estimates in the range 1.4-1.6, while a genetic analysis gave a central estimate of 1.2. This range of values is, consistent with 14 to 73 generations of human-to-human transmission having occurred in Mexico to late April. Transmissibility is therefore substantially higher than seasonal flu, and comparable with lower estimates of R0 obtained from previous influenza pandemics.


The WHO's latest bulletin:

Assessing the severity of an influenza pandemic
The H1N1 virus strain causing the current outbreaks is a new virus that has not been seen previously in either humans or animals. Although firm conclusions cannot be reached at present, scientists anticipate that pre-existing immunity to the virus will be low or non-existent, or largely confined to older population groups.

H1N1 appears to be more contagious than seasonal influenza. The secondary attack rate of seasonal influenza ranges from 5% to 15%. Current estimates of the secondary attack rate of H1N1 range from 22% to 33%.

... In the two largest and best documented outbreaks to date, in Mexico and the United States of America, a younger age group has been affected than seen during seasonal epidemics of influenza. Though cases have been confirmed in all age groups, from infants to the elderly, the youth of patients with severe or lethal infections is a striking feature of these early outbreaks.

In terms of population vulnerability, the tendency of the H1N1 virus to cause more severe and lethal infections in people with underlying conditions is of particular concern.

For several reasons, the prevalence of chronic diseases has risen dramatically since 1968, when the last pandemic of the previous century occurred. The geographical distribution of these diseases, once considered the close companions of affluent societies, has likewise shifted dramatically. Today, WHO estimates that 85% of the burden of chronic diseases is now concentrated in low- and middle-income countries. In these countries, chronic diseases show an earlier average age of onset than seen in more affluent parts of the world.

In these early days of the outbreaks, some scientists speculate that the full clinical spectrum of disease caused by H1N1 will not become apparent until the virus is more widespread....
 
Sorry, I was referring specifically to pandemic flu which is A type.
Still, the point was there have been a few H5N1 infections recorded in pigs.

But I'm not one to worry about a reassortment event until there's actual reason to worry. "Of all the gin joints in all the towns in all the world", will H1 really walk into H5's? ;)
 
If there was a decision to be made to choose one vaccine over another, then the decision would be more iffy.
Interpretation of what the WHO is saying about this does seem to involve a certain amount of reading between the lines (as well as compensating for language munged in transcription). When I encounter, say, this passage:

"As to stop potentially seasonal vaccine production, again there is still evidence lacking to make such a big move into saying if we need or we don't need much less seasonal vaccine for the next epidemic season. We are currently collecting with the manufacturers all data and all evidence on availability of enough material to make seasonal vaccine now. Potentially a recommendation towards stopping production of seasonal vaccine may come in a few weeks, if it does."

...I infer that the decision does potentially involve choosing one vaccine over another. Asked explicitly whether there is the capacity to do both at the same time, Dr. Kieny pointed to the unknown variables which could impact that. If it turns out that the yield is poor, or the effective dosage is high (or, worse, both), then the answer would appear to be no. She also clearly expressed uncertainty regarding how much vaccine has already been produced, saying "We hope to be able to have that by next week." (That is, this week). I understand that because WHO officials have to be cautious about public statements they make, Dr. Kieny may actually know more about where the U.S. production is than she is saying. Can you provide links to other sources which have been more forthcoming about this?

3 strains go into every annual flu vaccine. The 3 strains are always produced simultaneously by the manufacturers.
Not simultaneously at the same facility, if the Director of the Initiative for Vaccine Research at the World Health Organization knows anything about it:

"In terms of knowing if it possible to continue to make seasonal wild seed while already producing H1, it depends because you can't produce in the same manufacturing plant two influenza vaccines at the same time."

No one makes 1 or 2 strain flu vaccine. Flu vaccine has been trivalent for decades.
And yet, here we are, four decades since the last notable flu pandemic, following discussions on whether a pandemic vaccine would be added to the trivalent vaccine or distributed separately as a univalent vaccine, and whether it deserves enough priority to justify curtailing production of at least some components of the trivalent seasonal vaccine. It underscores my point: twenty years of experience in dealing with influenza is twenty years of no experience in dealing with pandemic influenza. This is not business as usual.

New companies moved into the flu vaccine market and all of them have ramped up production capacity. There is no reason they want that capacity sitting idle.
Idle manufacturing capacity does not appear to be much of an issue.

The pandemic flu plans have been under development for years.
The same could be said for the Maginot Line.

You sorely underestimate the quality of the health care system in the US and I assume in the other developed nations.
Without exploring all of the possible avenues of a response to that: When it comes to the ability of this health care system to respond to a major pandemic event, I find it hard to muster even cautious optimism.

And I am far from being alone in this:

"My hospital has almost no surge capacity; it is running full all the time," Panacek said. "If we had a 10% increase in the need for admissions because of flu, we would have nowhere in the hospital to put those patients. They would back up in the ER, and they would lie on gurneys for days."
 
Interpretation of what the WHO is saying about this does seem to involve a certain amount of reading between the lines (as well as compensating for language munged in transcription). When I encounter, say, this passage:

"As to stop potentially seasonal vaccine production, again there is still evidence lacking to make such a big move into saying if we need or we don't need much less seasonal vaccine for the next epidemic season. We are currently collecting with the manufacturers all data and all evidence on availability of enough material to make seasonal vaccine now. Potentially a recommendation towards stopping production of seasonal vaccine may come in a few weeks, if it does."

...I infer that the decision does potentially involve choosing one vaccine over another.
Not that I expect you to recall everything I've posted, especially something not perceived to be relevant at the time, but I said only the US had the luxury of current flu vaccine manufacturers that were almost finished with this year's vaccine. I said I was not sure about Europe's or Canada's production status, and that the southern hemisphere was faced with the dilemma of perhaps having to choose one over the other.



Asked explicitly whether there is the capacity to do both at the same time, Dr. Kieny pointed to the unknown variables which could impact that. If it turns out that the yield is poor, or the effective dosage is high (or, worse, both), then the answer would appear to be no. She also clearly expressed uncertainty regarding how much vaccine has already been produced, saying "We hope to be able to have that by next week." (That is, this week). I understand that because WHO officials have to be cautious about public statements they make, Dr. Kieny may actually know more about where the U.S. production is than she is saying. Can you provide links to other sources which have been more forthcoming about this?
Sure, she said something to the effect there was uncertainty regarding capacity for 700 million doses or 900 million. :rolleyes:

Perhaps you missed this from your link:
We would not want to have no seasonal influenza vaccine and we think we already have quite a lot of it produced.
and
And we know that they have produced for sure around 500 million doses of seasonal vaccine in 2009. So this we know for sure.
That tells me Canada and Europe might also have a fair amount of their vaccine ready since the US only made ~100 million doses last year. I doubt we would have 5 times that amount this year.



Not simultaneously at the same facility, if the Director of the Initiative for Vaccine Research at the World Health Organization knows anything about it:

"In terms of knowing if it possible to continue to make seasonal wild seed while already producing H1, it depends because you can't produce in the same manufacturing plant two influenza vaccines at the same time."
From your link:
This is why manufacturers for seasonal, for example, do the three strains one after the other. Some of the manufacturers have more than one production plant...
Those production plants can be in the same geographical location, including in the same building. Obviously each seed strain has to be isolated from each different seed strain. I certainly never suggested you would just mix the bunch up in the same room.



And yet, here we are, four decades since the last notable flu pandemic, following discussions on whether a pandemic vaccine would be added to the trivalent vaccine or distributed separately as a univalent vaccine, and whether it deserves enough priority to justify curtailing production of at least some components of the trivalent seasonal vaccine. It underscores my point: twenty years of experience in dealing with influenza is twenty years of no experience in dealing with pandemic influenza. This is not business as usual.
Once again, you are confusing news reports and official WHO and CDC statements with what is actually being discussed about the vaccine. For example, in your link Dr Kieny made the following comments:
We have been setting up an Advisory Committee that will provide policy recommendation to WHO on the use of this vaccine....

We are organizing, as I speak, a meeting that has been called by the Director-General in Geneva on 19 May with the heads of all the companies making influenza vaccines....

These are some of the factors that will be taken into consideration by this policy advisory group when it will work towards making potentially a recommendation to the Director-General that at one point it might be the time to "switch", if you mean "switch" is "stop seasonal”. But in the mean time, there may be recommendation coming much before that, could be next week, could be later also, it depends on the opinion of these experts and not on what I would think for example, or what the WHO Secretariat thinks, about starting large scale manufacturing.
That's political speak for, "I can't make an announcement yet," and "no one person makes the WHO decisions." It's also pretty strong language for "the answer is a go for a new vaccine."

This is also pretty strong language for "the answer is a go for a new vaccine."
Efforts are still going on in the WHO Collaborating Centres, at the CDC and elsewhere, to generate these strains for the manufacturers and we still expect that these would be available to the manufacturers most likely during the second half of May. We will post on our web site, as soon as the date is for sure, as well as a list of laboratories from which these seed strains will be available and the date, and this as soon as possible.
We have communicated with all manufacturers already, and have assured them and taken all steps to ensure that these seed strains will be available to all of them who so request to the WHO Collaborating Centres.

I must say that the manufacturers that we have had discussions with, have been very forthcoming and we hope that we will be able in a few days – maximum weeks – to announce that some agreement has been signed.

The public has most of the same information or at least a good idea about that information that this advisory group will base their decisions on. You seem to think the committee has some secret information not available to the rest of us, or perhaps you think their decision is unpredictable. Anyone who works in this field knows what the committee is going to recommend because we have most of the same information they have.




Idle manufacturing capacity does not appear to be much of an issue.
From your link:
There are also manufacturers who either have such a large capacity that even with these orders they have a lot of capacity to offer, some others have no pre-purchased doses. It is really a mixed picture. Before jumping ahead and saying how many doses are being locked in contracts, we really need to have more data. There has been one manufacturer who has said publicly, in a teleconference with the other manufacturers, that their company had currently locked into contract enough vaccine to vaccinate a little bit over 200 million people, but this particular manufacturer has a much larger production capacity. Even though we may seem large, this manufacturer still has a lot to offer for other countries.
And as I said, Sanofi just had a new facility approved for flu vaccine production announced on May 4th. After several years with a serious flu vaccine shortage, the US government has been taking action to increase production capacity. They have guaranteed purchases, but also in your link I noticed Dr K mentioned the US actually paid for some of the new plants.




The same could be said for the Maginot Line.
I'm sorry but I totally don't see the relevance. Could you possibly have a perfect plan in place before you ever had an actual event to test it in? Of course not. Even after testing and working the bugs out, the next pandemic would create new challenges.

I've seen a pretty good response in my state. I can't say about other areas of the country just yet.


Without exploring all of the possible avenues of a response to that: When it comes to the ability of this health care system to respond to a major pandemic event, I find it hard to muster even cautious optimism.

And I am far from being alone in this:

"My hospital has almost no surge capacity; it is running full all the time," Panacek said. "If we had a 10% increase in the need for admissions because of flu, we would have nowhere in the hospital to put those patients. They would back up in the ER, and they would lie on gurneys for days."
Surge capacity in hospitals hasn't really been needed yet. The initial crowds at the EDs were mostly not that sick and the issue was short lived. Sometime in the future, however, we'll be seeing the real surge with the really ill people. But I'm talking about realistic pandemic flu planning, not idealistic when I say the planned response has been excellent.

You're never going to get the public to tolerate the economic expenditure to have idle surge capacity available for pandemics. Just as we know what we should be doing to retrofit buildings and bridges for big earthquakes. People are unwilling to spend much money on future risks. Heck, most of them aren't willing to spend money on current risks like buying the very safest vehicles.

The one big problem I see that hasn't been addressed in our planning is sick people aren't willing to stay home for various reasons. I think we need to plan for that rather than plan unrealistically for sick people to stay home.

We have to be realistic and plan for overfilled medical facilities, just like we need to have in our pandemic plans a realistic approach to the fact sick people will not stay home. There's no point in planning a solution you know will not be carried out. So I don't see 'no surge capacity' as a problem of planning, that is a problem of public will.
 
Last edited:
More from the files of, "Like I've been saying...": The WHO May 12th news briefing transcript
Dr Nikki Shindo: We are only seeing the beginning of this outbreak. But perhaps soon it becomes more widely spread in covering or spreading to other regions. But so far, the data from the United States and Mexico suggest that about 10 percent, 9 to 10 percent of the positive cases, the confirmed cases require hospitalization. And the figures may evolve as more data become available, but at the snapshot we are seeing about 10 percent of hospitalization. This is clearly different from what we see from seasonal influenza. That is for sure. So that I think rightly urges the development and delivery of pandemic influenza vaccines because we are also facing the risk of having resistant viruses. Last year and previous seasons, we have seen widespread evidence of oseltamivir-resistant seasonal influenza.
The confirmed case count is not the actual case count.


As for comparing Mexico's severity to that in the US, "Like I've been saying....":
“Why only Mexico is having very severe cases?” The proportion of severe cases initially seemed to be very high in Mexico but not in the other countries. But as more information became available, the proportion of “mild” versus “severe” became very similar between these two countries – I am talking about the United States and Mexico.
You could not say from the initial cases in the US what the actual picture of severity was. Now that we have a few thousand cases, you can say more.


As for how severe the new strain is overall, this doesn't sound encouraging. Hopefully it is a overestimate of the fatality rate due to under counting the denominator.
out of every 1000 people who are confirmed with this disease, 14 of them will die....this is based on snapshot statistics and based on the best available information at the moment.
 
I said only the US had the luxury of current flu vaccine manufacturers that were almost finished with this year's vaccine.
I haven't had much luck finding a completely reliable source on that. THis May 6 Bloomberg report has Sanofi-Aventis, the world’s largest maker of seasonal flu vaccine, saying it plans to produce seasonal vaccine until August.

she said something to the effect there was uncertainty regarding capacity for 700 million doses or 900 million.
She was talking about global production of seasonal vaccine, and she qualified that with this: "it is very difficult to have a full knowledge of exactly how many because it depends what you take into consideration" as well as noting: "this would translate between at least one to two billion doses of H1N1 pandemic vaccine" (half a billion to one billion if it turns out that two doses are needed to confer protective immunity).

Once again, you are confusing news reports and official WHO and CDC statements with what is actually being discussed about the vaccine.
If the WHO and CDC statements are not reasonably indicative of what is actually being discussed, I don't see much point in them bothering to issue them.

The public has most of the same information or at least a good idea about that information that this advisory group will base their decisions on. You seem to think the committee has some secret information not available to the rest of us, or perhaps you think their decision is unpredictable. Anyone who works in this field knows what the committee is going to recommend because we have most of the same information they have.
Not sure which direction you're pointed in there, but they seem to be saying that not all of the necessary information is even available to them, and they're still trying to gather it, and that the decision will depend a lot on the outcome of that.

And as I said, Sanofi just had a new facility approved for flu vaccine production announced on May 4th.
Which, when operating at full capacity, will be capable of producing 100 million doses (of trivalent), raising Sanofi's total capacity to 150 million doses. Not sure when it is expected to reach full capacity. Production of Fluzone vaccine for the 2009-2010 season is already underway in the new facility -- which, I would assume, means that the facility will not be available for production of a pandemic vaccine until those lots are finished (unless they decide to switch to the pandemic vax), and since the facility was just licensed, I'd also assume that that won't be for some months.

I'm sorry but I totally don't see the relevance.
No, you do see the relevance: "Could you possibly have a perfect plan in place before you ever had an actual event to test it in? Of course not."

I've seen a pretty good response in my state. I can't say about other areas of the country just yet.
I can't even speak for my entire state, but as far as things go in my community, I know two things for certain: at least one child was allowed to attend the local elementary school for several days this week despite being visibly ill with cough and fever; and at least one of the two local pharmacies currently has no Tamiflu on the shelf. I continue to view response to this pandemic as largely a do-it-yourself proposition.

You're never going to get the public to tolerate the economic expenditure to have idle surge capacity available for pandemics. Just as we know what we should be doing to retrofit buildings and bridges for big earthquakes. People are unwilling to spend much money on future risks.
Agreed. More support for the DIY approach. Of course, should I have another spontaneous pneumo like the one I had a couple of months ago, my chances of successfully dealing with that myself aren't nearly as good as my chances of handling a case of flu, so a pandemic would pose a risk to someone like me even if had a guarantee that I wouldn't become infected.

The one big problem I see that hasn't been addressed in our planning is sick people aren't willing to stay home for various reasons. I think we need to plan for that rather than plan unrealistically for sick people to stay home.
I agree. Especially when it comes to health care workers. One visit I made to a local clinic a while back really stuck in my mind because the aide who came in to do my vitals looked a little under the weather, and when I asked how she was feeling, she said she really ought to be home in bed but had already used up her allotted sick days. Being at high risk from respiratory infection of any kind, I find that completely unacceptable. I expect to run a gauntlet in the waiting room (which is one reason that my first choice is to avoid the place altogether), but when a direct consequence of their idiotic policies is to put me in face-to-face contact with someone who is obviously ill, it doesn't do much to instill faith in the quality of the health care system in the U.S. Sorry about that.
 
I haven't had much luck finding a completely reliable source on that. THis May 6 Bloomberg report has Sanofi-Aventis, the world’s largest maker of seasonal flu vaccine, saying it plans to produce seasonal vaccine until August.

She was talking about global production of seasonal vaccine, and she qualified that with this: "it is very difficult to have a full knowledge of exactly how many because it depends what you take into consideration" as well as noting: "this would translate between at least one to two billion doses of H1N1 pandemic vaccine" (half a billion to one billion if it turns out that two doses are needed to confer protective immunity).
It's not luck, it's expertise, something you still don't seem to recognize you lack.

And we were talking about the fact the US supply of seasonal flu vaccine is almost ready and that would free up production capacity as opposed to deciding between the two vaccines. You seem to have lost track of the discussion. I never said there was going to be enough new vaccine for everyone who needed it. Just that the US could get started making it fairly quickly and we'd still have plenty of seasonal flu vaccine.

As for the Bloomberg article, "Like I was saying"... don't expect a quadrivalent seasonal+swine vaccine.
May 6 (Bloomberg) -- The World Health Organization has determined that at least two influenza shots will be needed to protect against both the seasonal form of the disease and the new swine flu.

"Like I was saying"...I wasn't sure where the European production of seasonal vaccine was at.
“If we stop too fast, to produce the vaccine against the new strain, if it is decided to produce the new strain, we will have a lower amount of seasonal,” Jacques Berger, the head of the company’s Sanofi Pasteur vaccine unit in France, said in an interview yesterday.

"Like I was saying"...The southern hemisphere is going to have a different decision to make.
“It would probably be premature to make the decision at this stage” to switch to making a vaccine for swine flu, said Ian Barr, deputy director of the WHO Collaborating Center for Influenza in Melbourne, one of four laboratories globally that provides WHO with data on flu and advises which strains to include in vaccines.



If the WHO and CDC statements are not reasonably indicative of what is actually being discussed, I don't see much point in them bothering to issue them.
I know exactly what the comments indicate. And I've been trying to share that with you but you continue with the pissing contest. Instead of a discussion, you seem to only want to find something I've been wrong about.



Not sure which direction you're pointed in there, but they seem to be saying that not all of the necessary information is even available to them, and they're still trying to gather it, and that the decision will depend a lot on the outcome of that.
Just because you aren't sure what the advisory committee is going to say doesn't mean other people who know more about it aren't sure.



Which, when operating at full capacity, will be capable of producing 100 million doses (of trivalent), raising Sanofi's total capacity to 150 million doses. Not sure when it is expected to reach full capacity. Production of Fluzone vaccine for the 2009-2010 season is already underway in the new facility -- which, I would assume, means that the facility will not be available for production of a pandemic vaccine until those lots are finished (unless they decide to switch to the pandemic vax), and since the facility was just licensed, I'd also assume that that won't be for some months.
Where do you get the idea the seasonal vaccine production is already underway in the new Sanofi plant? The article announced the plant is now licensed for flu vaccine, not that production had begun.



I can't even speak for my entire state, but as far as things go in my community, I know two things for certain: at least one child was allowed to attend the local elementary school for several days this week despite being visibly ill with cough and fever; and at least one of the two local pharmacies currently has no Tamiflu on the shelf. I continue to view response to this pandemic as largely a do-it-yourself proposition.
Your public health department has the Tamiflu and are seeing to it that it gets properly triaged to the right people because there is not enough to waste on everyone who wants it. I suggest you contact them and ask how you should plan to get some if you develop symptoms.

And lots of kids are going to school ill as are their parents going to work ill. Trying to keep every ill person home has not been pushed as a useful control measure in the current circumstances. The measure has to be effective to matter if it is used. Not that it doesn't gross me out to see people coughing at the grocery store. I give them dirty looks if I make eye contact with them to let them feel the wrath of social displeasure. ;)



...
I agree. Especially when it comes to health care workers. One visit I made to a local clinic a while back really stuck in my mind because the aide who came in to do my vitals looked a little under the weather, and when I asked how she was feeling, she said she really ought to be home in bed but had already used up her allotted sick days. Being at high risk from respiratory infection of any kind, I find that completely unacceptable. I expect to run a gauntlet in the waiting room (which is one reason that my first choice is to avoid the place altogether), but when a direct consequence of their idiotic policies is to put me in face-to-face contact with someone who is obviously ill, it doesn't do much to instill faith in the quality of the health care system in the U.S. Sorry about that.
I can understand your concern. I am always disappointed at the infection control in my own doctor's office. So I try to function with the philosophy: what can I do to protect myself knowing other people are going to be spreading infection? In this case, in order to stay sane, access to Tamiflu is my back up plan. I resigned myself on the first day or so of this that I would not be able to avoid the virus 100%.

My first line of defense is liberal use of the waterless hand cleaner that I carry in my purse and have more of in my car. And I have a face mask in my purse should I find myself in an elevator or similar close confinement with an ill person.

-
 
And we were talking about the fact the US supply of seasonal flu vaccine is almost ready and that would free up production capacity as opposed to deciding between the two vaccines.
Yes, I believe you've stated that as "a fact" several times now. What you haven't done is provide a link to a source of that information, pointing instead to your own vast expertise. I've provided a link to a source which indicates that there is potentially a problem with the B component. I'm not looking to win here, I just want to know the truth about the current status of U.S. vaccine production. I'm sorry if you are offended by my reluctance to take your word for it.

Just because you aren't sure what the advisory committee is going to say doesn't mean other people who know more about it aren't sure.
Actually, I was going more by the fact that WHO Director of the Initiative for Vaccine Research clearly expresses the fact that she herself isn't sure what the advisory committee is going to say.

Where do you get the idea the seasonal vaccine production is already underway in the new Sanofi plant?
I got that from this news article. I have to admit that I found that a bit surprising to say the least, but I don't have all that much to go on, as I don't have a mole inside Sanofi. Do you?

Your public health department has the Tamiflu and are seeing to it that it gets properly triaged to the right people because there is not enough to waste on everyone who wants it. I suggest you contact them and ask how you should plan to get some if you develop symptoms.
Like I'd really depend on that. Any idea what kind of lag time I'd be looking at there? I've had mine in hand for well over a year. I only asked at the pharmacy out of curiosity. I know that shipments in France were frozen at one point in response to a run on the pharmacies, but I haven't heard about anything like that here. Have you?

And lots of kids are going to school ill as are their parents going to work ill.
With so many parents who seem to see government sponsored child care as the primary purpose of public school in this country, where else are the kids going to go?

Trying to keep every ill person home has not been pushed as a useful control measure in the current circumstances.
Actually, it has. The CDC started out recommending that schools close when cases were identified. When large numbers of serious cases failed to materialize, they changed that recommendation, to this:

"Students, faculty and staff who appear to have an influenza-like illness at arrival or become ill during the day should be isolated promptly in a room separate from other students and sent home."

Once the virus is known to already be widespread in the community, I guess it could be considered less of a big deal, but in my community, it isn't. Yet. As far as I know. I think what's going on is that most people gauge the risk by the amount of media attention it receives, school officials included. We are just not set up to deal with a thing like this.
 
Yes, I believe you've stated that as "a fact" several times now. What you haven't done is provide a link to a source of that information,
Crap, Dym, I quoted your own source!!!!!!!!!!!!!!!!!!!!!! I even bolded it for you.
We would not want to have no seasonal influenza vaccine and we think we already have quite a lot of it produced....
...we know that they have produced for sure around 500 million doses of seasonal vaccine in 2009. So this we know for sure.
What do you think ALREADY HAVE FOR SURE 500 MILLION DOSES OF SEASONAL VACCINE means? That they have 250 million doses of vaccine for each of 2 strains and none of the 3rd strain? :rolleyes: I'm not going to hunt down the source of information I read 2+ weeks ago that discussed the US vaccine supply when your own source says what it does on the subject.

Have you posted your source that the US manufacturers were held up trying to produce the B strain component? I don't seem to recall seeing it.

Actually, I was going more by the fact that WHO Director of the Initiative for Vaccine Research clearly expresses the fact that she herself isn't sure what the advisory committee is going to say.
Because there are all sorts of details the biggest one being the southern hemisphere's possible need to forgo one of the seasonal components that I haven't said are clear yet either. Dr K is talking about not being sure of the details. If you don't think the rest of us know at this point a swine flu vaccine will be produced, that's your problem. You can wait for the WHO announcement tomorrow or Friday.


I got that from this news article. I have to admit that I found that a bit surprising to say the least, but I don't have all that much to go on, as I don't have a mole inside Sanofi. Do you?
It's surprising all right since the article doesn't say anywhere in it that the facility is already operating!!!!
The new facility will produce 100 million doses when operating at full capacity.



Like I'd really depend on that. Any idea what kind of lag time I'd be looking at there? I've had mine in hand for well over a year.
Then why are you so uptight about the schools not closing?

I only asked at the pharmacy out of curiosity. I know that shipments in France were frozen at one point in response to a run on the pharmacies, but I haven't heard about anything like that here. Have you?
Roche made a public announcement they were going to ship to government agencies and none to the private sector in the short term. This is not secret or obscure news.

It is also consistent with the pandemic flu plan. The pharmaceutical companies have (in the Western countries at least) been very conscientious about shipping vaccines and drugs to where they are needed as determined by the public health agencies. The drug companies have not tried to sell to the highest bidder or anything like that.

Actually, it has. The CDC started out recommending that schools close when cases were identified. When large numbers of serious cases failed to materialize, they changed that recommendation, to this:
I already posted about this.

Once the virus is known to already be widespread in the community, I guess it could be considered less of a big deal, but in my community, it isn't. Yet. As far as I know. I think what's going on is that most people gauge the risk by the amount of media attention it receives, school officials included. We are just not set up to deal with a thing like this.
Closing schools did little to stop the spread. You may not like that, and from your health description, I understand. But there is no sense using measures that don't do much good.


Just wondering, when the WHO announces the recommendation to produce the swine flu vaccine will you give up the pissing contest?
 
Last edited:
What do you think ALREADY HAVE FOR SURE 500 MILLION DOSES OF SEASONAL VACCINE means?
What gave you the idea that they were talking about the U.S. supply there? Do you know what the "W" in "W.H.O." stands for?

I'm not going to hunt down the source of information I read 2+ weeks ago that discussed the US vaccine supply when your own source says what it does on the subject.
I'll bet you're not.

Have you posted your source that the US manufacturers were held up trying to produce the B strain component? I don't seem to recall seeing it.
There seems to be quite a bit that you're either not seeing or not recalling here. It's in post #325 above, the link captioned "Actually, there is a bit of a snag." In case you still can't find it: here it is again.

It's surprising all right since the article doesn't say anywhere in it that the facility is already operating!!!!
Evidently, your reading comprehension goes in the toilet when you get upset. Paragraph four in its entirety then:

"In total, Sanofi Pasteur will have a capacity of approximately 150 million doses of trivalent seasonal influenza vaccine per year in the U.S. - 50 million doses from the existing facility and 100 million doses from the new facility when it is operating at full capacity. Production of Fluzone vaccine for the 2009-2010 season is already underway in the new facility."

Closing schools did little to stop the spread.
That one I think you should at least attempt to provide some evidence for.
 
Because there are all sorts of details the biggest one being the southern hemisphere's possible need to forgo one of the seasonal components

Our season starts in a little under three weeks.
The flu vaccine has been available since mid Feb and I assume everyone who is going to has already had it.
Perhaps you mean Winter 2010?
 
Our season starts in a little under three weeks.
The flu vaccine has been available since mid Feb and I assume everyone who is going to has already had it.
Perhaps you mean Winter 2010?
Good point. I think we were glossing over that fact.

The soonest a new vaccine could be out is 4 months after the decision to go and probably just a tad longer.

This flu vaccine timeline might help sort out the issues. Production occurs from Jan to July, with the strains chosen Feb to March. Testing the lots occurs from June to October, packaging from July to December and shipping starts in August.

Adapting that to the southern hemisphere you'd likely see production from June to January. So for the 2009 season, the vaccine would be ready to be shipped, but the production facilites are about to be committed for the 2010 vaccine. If they make the new vaccine (and I bet they will), then you might see a delay in the 2010 vaccine, or at least that might go into the decision process.

However, in looking for this info, I found numerous references to companies committed to making the new vaccine.



Here's part of the problem in figuring the stage of production:

INFLUENZA VACCINE - Issues Related to Production, Distribution, and Public Health Messages
FDA selects the three virus strains that will make up the vaccine for the upcoming season usually between late February and early March; once these selections are made, the manufacturers, using samples of each selected virus strain, develop seed viruses that are suitable for subsequent vaccine production. Manufacturers reported that the timeline for FDA’s strain selection and the subsequent distribution of samples of strains to develop seed viruses does not allow them enough time to produce all three virus strains in time for the fall vaccination period. As a result, manufacturers consult with CDC and FDA, assess preliminary data, and complete their own analyses as to what FDA’s choice of virus strains for the upcoming season might be. Manufacturers usually begin producing one of the influenza virus strains that they believe will be included in the vaccine in January in advance of FDA’s strain selection.
(emphasis mine)



So normally the Southern hemisphere would be starting on one of the seasonal strains in June in order to have trivalent vaccine ready by June the following year. Production capacity could make the difference since if there is spare capacity the strains could be grown simultaneously instead of sequentially which is what is done by the smaller companies.
 
Last edited:

ISF - Join now!

Every member here is approved by hand. No bots, no spam, just people who care about evidence and honest debate.

Membership is free!

Create your free account

Back
Top Bottom